Sanofi Rilzabrutinib Wins Japan Orphan Status
Paris, March 2, 2026 Sanofi announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug...
Immune Thrombocytopenia
Advertisement
Sanofi’s Wayrilz Approved in the U.S. as First BTK Inhibitor for Immune Thrombocytopenia
Sanofi has secured U.S. FDA approval for Wayrilz (rilzabrutinib), marking the first Bruton’s tyrosine kinase (BTK) inhibitor approved for...
Advertisement
